Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults.

Trial Profile

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 12 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 12 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top